U.S. Household Products Stock News

Blackstone (BX) has been catching some investor eyes lately, not because of a headline-grabbing deal or market-moving announcement, but simply due to the steady rhythm of its recent price swings. Moves like these often prompt investors to pause as they weigh whether the market has missed something in Blackstone’s math or if the shares are already reflecting all the growth that is yet to come. Taking a step back, momentum has generally been in Blackstone’s favor this year. While the most...

If you have ever wondered whether Wyndham Hotels & Resorts (WH) is ready for its next chapter, the latest headlines offer something to think about. The company has not just opened a renovated four-star hotel in Conegliano, Italy; it also inked a new property deal in Darbhanga, India, and is taking steps to cater to a rising wave of Indian travelers in Greece. These moves come as part of Wyndham’s ongoing push to expand into high-potential markets where competition is still up for grabs. This...

City Holding (CHCO) just made a statement that is hard to ignore if you are weighing your options with the stock. The company boosted its quarterly dividend by 10%, up to 87 cents per share, for shareholders of record as of mid-October. This jump sends a clear message that management is confident in City Holding’s underlying strength and its ability to support bigger payouts, a signal that rarely goes unnoticed by the market. Following news of the dividend hike, City Holding’s shares have...

Recent analyst reports indicate that Travelers Companies may be poised for a positive earnings surprise ahead of its upcoming quarterly results, as highlighted by a strong Earnings ESP figure and upward earnings revisions. Travelers' continued heavy investment in technology and analytics, including AI and data tools, is improving underwriting and claims processing, positioning the company at the forefront of innovation in the property-casualty insurance sector. We'll explore how heightened...

If you’ve been tracking VanEck ETF Trust, VanEck Gold Miners ETF (ARCA:GDX), you know something is up. Gold is on pace for its second-best run in fifty years, reportedly rising over 43% as investors respond to a mix of global uncertainty and shifting monetary policies. This kind of rally has brought gold mining ETFs like GDX into the spotlight, with many watching closely as institutional investors still seem hesitant to pile in. China’s continued heavy gold imports, aiming to diversify and...

Ollie's Bargain Outlet Holdings (OLLI) is once again in the spotlight after its latest surge in revenue and a rapidly expanding customer base have investors taking a closer look. The company’s aggressive growth strategy seems to be meeting the moment, capitalizing on shoppers’ hunt for value in a still-uncertain economy. For many, the big question is whether these moves are enough to unlock hidden value that markets might be overlooking. Over the past year, Ollie’s shares have outpaced much...

In recent days, NOV Inc. secured a major contract to provide its APL Submerged Swivel and Yoke system for Argentina’s first-ever offshore floating LNG project, with industry partners backing the initiative. This marks a key milestone for NOV as it enters Argentina’s FLNG sector, reinforcing its position in supporting emerging energy markets. At the same time, NOV is contending with a sharp drop in profitability, contracting margins, and fewer new orders, prompting management to signal...

Moody's just made headlines with the launch of Agentic Solutions, its next-generation suite of AI-powered tools meant to transform high-stakes decision-making across finance, risk, and strategy. The new platform is built on Moody's vast data estate, using coordinated AI agents to automate knowledge-intensive workflows that can drain hours from teams in heavily regulated sectors. For investors trying to gauge the impact, this move signals how Moody's is cementing its place in the rapidly...

Here’s something to give investors pause: Amkor Technology (AMKR) just executed a $500 million senior notes offering while simultaneously announcing its plan to redeem $400 million worth of older, higher-interest debt. This shuffle in the capital structure, paired with its recent exit from the PHLX Semiconductor Sector Index, isn’t the type of headline that usually turns heads. Still, these moves signal management’s intent to control costs and free up cash, even as operational headwinds like...

If you are tracking Weibo (NasdaqGS:WB), you probably noticed some extra attention this week. The company was just added to the S&P Global BMI Index, a move that tends to create fresh buzz among investors. Index inclusions like this typically draw a wave of new interest from institutional investors and funds that track the index, potentially shaking up trading volumes and sentiment, even if nothing fundamental about the business has changed overnight. The backdrop here is interesting. Over...

Costamare recently outperformed broader market indices, with analysts projecting its upcoming earnings per share to increase by 2.94% compared to the same quarter last year. Analyst confidence in Costamare's near-term prospects has been underscored by its top Zacks Rank, indicating strong expectations for continued profit momentum. Given this renewed analyst optimism and projected earnings growth, we'll explore how these factors impact Costamare's investment narrative and future outlook. AI...

Medtronic recently received U.S. FDA approval for its Altaviva™ device, a minimally invasive implantable therapy designed to treat urge urinary incontinence with features such as a 15-year battery lifespan and MRI compatibility. This approval positions Medtronic as the only company offering a full portfolio of neuromodulation therapies for bladder control, addressing a major unmet clinical need affecting millions of U.S. adults. We'll explore how this milestone strengthens Medtronic's...

CarMax (KMX) delivered earnings growth of 24.8% over the last twelve months, a sharp contrast to its five-year average of negative 18% per year. The stock is trading at $44.86, with earnings per share forecast to increase by 15.25% annually, just shy of the US market projection of 15.5% per year. While revenue growth is expected to lag at 0.5% per year, investors may be taking note of the company’s high-quality earnings and sector-relative value, tempered by a cautious outlook on financial...

HF Sinclair (NYSE:DINO) has landed in the spotlight after a string of upbeat analyst updates, including an upgrade to a Zacks Rank #2 (Buy). Investors are taking note, especially as several recent revisions have boosted earnings estimates and highlighted the company's momentum and valuation appeal. These kinds of favorable signals often generate buzz among those wondering whether HF Sinclair's business trajectory is turning a corner. All this attention comes after a year in which HF Sinclair...

Lennox International (LII) just confirmed what many investors have been quietly hoping for, reporting another round of double-digit earnings per share growth and a revenue jump that topped analyst forecasts. This latest update also came with strong EBITDA results and a continued commitment to returning cash to shareholders, as the board approved a quarterly dividend. With headlines pointing to disciplined cost controls and management still aligned closely with stockholders, Lennox is putting...

If you're trying to decide what to do with DexCom (DXCM) shares this week, you're hardly alone. A trio of big developments has landed in rapid succession. Biolinq just won FDA de novo clearance for a needle-free continuous glucose monitor, representing a direct challenge to DexCom’s core market. At nearly the same time, DexCom highlighted new clinical and cost-effectiveness data for its own biosensing technology at the high-profile EASD conference. In addition, CEO Kevin R. Sayer is taking a...

If you are wondering what to do with your Pfizer shares right now, you are not alone. Maybe you are eyeing the stock’s steady slide over the past year and thinking of bailing out, or perhaps you are looking for an undervalued giant ready for a comeback. In either case, there is more to the story than just price charts and headlines. Pfizer’s stock is trading at $23.76 as of the most recent close, with year-to-date returns at -10.7% and a one-year decline of -12.6%. Over three years, the price...

Viridian Therapeutics recently announced the completion of enrollment for its REVEAL-1 and REVEAL-2 phase 3 clinical trials evaluating VRDN-003 for active and chronic thyroid eye disease (TED), alongside positive topline results for its phase 3 trials of veligrotug in TED patients. These clinical programs mark the first global phase 3 data in chronic TED to show statistically significant improvements in diplopia response and resolution, underscoring the potential of VRDN-003 as a...

Casey’s General Stores recently announced a partnership with K9s For Warriors to fund the training of a service dog for military veterans, and a collaboration with GSTV to launch branded video content across its fuel dispensers at over 2,900 locations. These initiatives enhance Casey’s community engagement efforts while substantially expanding its digital retail media footprint across its store network. We'll look at how the expansion of Casey's digital retail media network through the GSTV...

In a significant regulatory development earlier this week, the Federal Housing Finance Agency announced Fannie Mae and Freddie Mac will now permit lenders to use alternative credit scoring models, including VantageScore, in place of Fair Isaac Corporation’s FICO scores for home loan assessments. This move offers government endorsement to competing credit scoring providers and challenges FICO’s longstanding dominance in mortgage underwriting, raising concerns about its future market share and...

If you are watching Scholar Rock Holding (SRRK), Tuesday’s FDA decision likely gave you a moment of pause. The agency issued a Complete Response Letter for the company’s application to bring apitegromab, its lead candidate for spinal muscular atrophy, to market. The key thing to note is that the FDA’s rejection did not stem from concerns about the drug’s efficacy or safety. Instead, the stumbling block was related to manufacturing, specifically observations from an inspection of a third-party...

If you have been watching Boston Scientific (BSX), the company's latest moves might make you pause before your next trade. Boston Scientific’s recent acquisitions of Intera Oncology and SoniVie have generated attention, expanding its reach in minimally invasive therapies and strengthening its capabilities in the liver cancer and hypertension spaces. Meanwhile, the new WATCHMAN FLX Pro device has achieved CE Mark approval. This milestone highlights progress in structural heart care. These...

If you hold or are eyeing W. P. Carey (WPC), the latest moves probably have you leaning in. After a six-day losing streak, shares have started to edge upward just as the company announced another bump in its quarterly dividend. This dividend raise comes against a backdrop of ongoing challenges, with high mortgage rates and rising construction costs pressuring the sector. Still, W. P. Carey is clearly signaling it wants to remain a draw for income-focused investors as markets digest recent...

If you’ve been watching Autodesk (ADSK) lately, the recent string of announcements might have you wondering if it’s finally time to take a closer look at the stock. The company’s second-quarter results topped expectations, and leadership dialed guidance higher for both revenue and free cash flow this year. That confidence wasn’t built on numbers alone. High-profile deals, such as enhanced integrations with Aurigo Software and new collaborations with the New England Patriots and Eaton, signal...